Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
CGD NOTES
April 08, 2024
This CGD Note outlines a proposal for a New Compact between Gavi and partner countries. We outline a package of policy shifts for Gavi to consider, in line with the core approach of prioritising country ownership and financing of the highest priority vaccines while health aid is provided at the marg...
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
CGD NOTES
March 26, 2024
This note further unpacks why research publishing reform should be a global priority using the Importance-Tractability-Neglectedness (ITN) framework—a framework that estimates the value of allocating marginal resources to solving a problem, considering its significance, feasibility for intervention,...
Mar
27
2024
VIRTUAL
11:00—12:00 PM EST / 3:00 - 4:00 PM GMT
March 11, 2024
In this panel event, Ashley Farley from the Gates foundation will outline the refreshed policy and be joined by leading experts and champions of research publishing reform. The panel will explore the multifaceted nature of the problem, delving into challenges faced by researchers working in Africa; ...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...